<?xml version='1.0' encoding='utf-8'?>
<document id="23716892"><sentence text="Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats."><entity charOffset="30-42" id="DDI-PubMed.23716892.s1.e0" text="voriconazole" /></sentence><sentence text="The objective was to study the of drug-drug interaction between voriconazole and oral hypoglycemic agents in normal and alloxan induced diabetic rats"><entity charOffset="64-76" id="DDI-PubMed.23716892.s2.e0" text="voriconazole" /><entity charOffset="120-127" id="DDI-PubMed.23716892.s2.e1" text="alloxan" /><pair ddi="false" e1="DDI-PubMed.23716892.s2.e0" e2="DDI-PubMed.23716892.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s2.e0" e2="DDI-PubMed.23716892.s2.e1" /></sentence><sentence text="" /><sentence text="The study was designed in two phases" /><sentence text=" In the first phase, influence of glibenclamide (0"><entity charOffset="34-47" id="DDI-PubMed.23716892.s5.e0" text="glibenclamide" /></sentence><sentence text="45 mg/kg, p" /><sentence text="o" /><sentence text=") and pioglitazone (2"><entity charOffset="6-18" id="DDI-PubMed.23716892.s8.e0" text="pioglitazone" /></sentence><sentence text="7 mg/kg, p" /><sentence text="o" /><sentence text=" once daily) on blood glucose levels in normoglycemic rats was studied and then influence of voriconazole (18 mg/kg, p"><entity charOffset="22-29" id="DDI-PubMed.23716892.s11.e0" text="glucose" /><entity charOffset="93-105" id="DDI-PubMed.23716892.s11.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.23716892.s11.e0" e2="DDI-PubMed.23716892.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s11.e0" e2="DDI-PubMed.23716892.s11.e1" /></sentence><sentence text="o" /><sentence text=" twice daily" /><sentence text=") pre-treatment on the hypoglycemic activity studied" /><sentence text=" Simultaneously the influence of voriconazole treatment for seven consecutive days (per se effect) on blood glucose levels was also studied in normoglycemic rats"><entity charOffset="33-45" id="DDI-PubMed.23716892.s15.e0" text="voriconazole" /><entity charOffset="108-115" id="DDI-PubMed.23716892.s15.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23716892.s15.e0" e2="DDI-PubMed.23716892.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s15.e0" e2="DDI-PubMed.23716892.s15.e1" /></sentence><sentence text=" In the second phase of the study alloxan-induced diabetic rats were used to find out the influence of voriconazole pre-treatment on glibenclamide and pioglitazone induced hypoglycemic effect in pathophysiological condition"><entity charOffset="34-41" id="DDI-PubMed.23716892.s16.e0" text="alloxan" /><entity charOffset="103-115" id="DDI-PubMed.23716892.s16.e1" text="voriconazole" /><entity charOffset="133-146" id="DDI-PubMed.23716892.s16.e2" text="glibenclamide" /><entity charOffset="151-163" id="DDI-PubMed.23716892.s16.e3" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e0" e2="DDI-PubMed.23716892.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e0" e2="DDI-PubMed.23716892.s16.e1" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e0" e2="DDI-PubMed.23716892.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e0" e2="DDI-PubMed.23716892.s16.e3" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e1" e2="DDI-PubMed.23716892.s16.e1" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e1" e2="DDI-PubMed.23716892.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e1" e2="DDI-PubMed.23716892.s16.e3" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e2" e2="DDI-PubMed.23716892.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23716892.s16.e2" e2="DDI-PubMed.23716892.s16.e3" /></sentence><sentence text=" Blood samples were collected from retro orbital plexus at regular intervals of 0" /><sentence text="0, 0" /><sentence text="5, 1" /><sentence text="0, 2" /><sentence text="0, 4" /><sentence text="0, 8" /><sentence text="0, 12" /><sentence text="0, 18" /><sentence text="0 and 24" /><sentence text="0 h after drug treatment" /><sentence text=" All the blood samples were analyzed for plasma glucose by glucose oxidase peroxidase method (GOD/POD)"><entity charOffset="48-55" id="DDI-PubMed.23716892.s27.e0" text="glucose" /><entity charOffset="59-66" id="DDI-PubMed.23716892.s27.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23716892.s27.e0" e2="DDI-PubMed.23716892.s27.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s27.e0" e2="DDI-PubMed.23716892.s27.e1" /></sentence><sentence text="" /><sentence text="The therapeutic dose of voriconazole potentiates the hypoglycemic activity of glibenclamide and pioglitazone both in normoglycemic and diabetic rats respectively"><entity charOffset="24-36" id="DDI-PubMed.23716892.s29.e0" text="voriconazole" /><entity charOffset="78-91" id="DDI-PubMed.23716892.s29.e1" text="glibenclamide" /><entity charOffset="96-108" id="DDI-PubMed.23716892.s29.e2" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.23716892.s29.e0" e2="DDI-PubMed.23716892.s29.e0" /><pair ddi="false" e1="DDI-PubMed.23716892.s29.e0" e2="DDI-PubMed.23716892.s29.e1" /><pair ddi="false" e1="DDI-PubMed.23716892.s29.e0" e2="DDI-PubMed.23716892.s29.e2" /><pair ddi="false" e1="DDI-PubMed.23716892.s29.e1" e2="DDI-PubMed.23716892.s29.e1" /><pair ddi="false" e1="DDI-PubMed.23716892.s29.e1" e2="DDI-PubMed.23716892.s29.e2" /></sentence><sentence text="" /><sentence text="The results indicate that the dose of oral hypoglycemic agents needs to be adjusted if co-administered with voriconazole"><entity charOffset="108-120" id="DDI-PubMed.23716892.s31.e0" text="voriconazole" /></sentence><sentence text="" /></document>